Live Dana-Farber Cancer Institute News with Latest Updates

Live Dana-Farber Cancer Institute news and developments with the latest updates. Check out current Dana-Farber Cancer Institute news stories and find out what happened, what is going on with Dana-Farber Cancer Institute. Recent news updates about Dana-Farber Cancer Institute
Immunotherapy Combination Improves Outcomes in Advanced Kidney Cancer
Dana-Farber Cancer Institute earns “LGBTQ Health Care Equality Leader” Designation in Human Rights Campaign
Daily coffee consumption associated with improved survival in patients with metastatic colorectal cancer
Study provides molecular look at how healthy muscle adapts to exercise
Study sheds light on some tumors’ ability to evade a promising immunotherapy strategy
Dana-Farber opens clinical trial to evaluate simple blood test for many types of cancer
Dozier Gardner Family Announces Gift to Establish Fund at Dana-Farber Cancer Institute
Dana-Farber researcher awarded Victoria Mock New Investigator Award 9 September
Dana-Farber Cancer Institute to establish Benderson Family Program for triple-negative breast cancer
Dana-Farber collaborates with Mass. Eye and Ear to rebuild damaged corneas using patients’ own stem cells for first
Dana-Farber launches new Center for prevention and treatment of BRCA-related cancers
Using models, 3D printing to study common heart defect
Dana-Farber study advances understanding of rare sarcoma
Dana-Farber/Brigham and Women’s Cancer Center is ranked best in New England
Dana-Farber to offer first CAR T-cell therapy for mantle cell lymphoma following FDA approval
Prostate cancer metastasis linked to revival of dormant molecular program
Three Dana-Farber physician scientists receive Doris Duke Charitable Foundation 2020 Clinical Scientist Development
Statement on U.S. Court of Appeals ruling regarding joint inventorship of six immnunotherapy patents
St. Jude researchers create an analytic tool that opens a new frontier of cancer discovery
How cancer drugs find their targets
Dana-Farber faculty recognized with AACR 2020 Team Science Awards
Dana-Farber researcher receives highest honor from Society for Immunotherapy of Cancer
Online program significantly improves insomnia in adolescent and young adult cancer survivors, study finds
Vitamin D May Help Prevent a Common Side Effect of Anti-Cancer Immunotherapy
Cigall Kadoch, PhD, to receive 2020 AACR Award for Outstanding Achievement in Basic Cancer Research
New technique may quickly and accurately predict effective therapies in solid tumors
Dana-Farber/Boston Children’s named a top pediatric cancer program
Drug with new approach on impeding DNA repair shows promise in first clinical trial
Patients with multiple myeloma and CHIP often have worse outcomes following autologous stem cell transplant
Inherited mutation increases risk of prostate cancer in men of African descent
Genomic test accurately identifies patients with smoldering multiple myeloma
Study shows comprehensive genomic profiling identified co-occurring alterations that may cause treatment resistance
Study reveals factors influencing outcomes in advanced kidney cancer treated with immunotherapy
Dana-Farber researchers present key studies at ASCO annual meeting
Multinational study identifies high risk to cancer patients diagnosed with COVID-19
Phyllis F. Cantor Center for Research in Nursing and Patient Care Services awarded two major research grants
Scientists find a new way to reverse symptoms of Fragile X
Dana-Farber to test blood cancer drug in COVID-19 patients
Three Dana-Farber faculty members elected as Fellows of American Association for Cancer Research
Study takes most comprehensive look to date at connection between ancestry and molecular makeup of cancer
Immune system changes occur early in development of multiple myeloma, study finds
Dana-Farber Cancer Institute faculty recognized as 2020 ASCO leaders in cancer research and care
Dana-Farber Cancer Institute faculty recognized as 2020 ASCO leaders in cancer care
Ludwig Harvard Co-Director George Demetri wins Karnofsky Award
New targeted agent produces considerable responses in trial with patients with uterine serous carcinoma
SHE Center at Dana-Farber and Silverberry Genomix form SHE Biobank
Small Molecule Activator of Tumor-Suppressor Protein Kills T-Cell Acute Lymphoblastic Leukemia Cells
Massive study reveals how “hypermutated” malignant brain tumors with many mutations escape